Silvant Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Silvant Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.46M	Sell	18,126 -132	-0.7%	-$39.8K	0.16%	82
2026 Q1	$6.04M	Buy	18,258 +294	+2%	+$100K	0.21%	57
2025 Q4	$7.14M	Buy	17,964 +288	+2%	+$127K	0.24%	48
2025 Q3	$8.06M	Sell	17,676 -1,671	-9%	-$680K	0.28%	45
2025 Q2	$6.31M	Buy	19,347 +3,152	+19%	+$872K	0.24%	57
2025 Q1	$4.37M	Hold	16,195	–	–	0.2%	64
2024 Q4	$3.81M	Hold	16,195	–	–	0.16%	81
2024 Q3	$4.45M	Buy	16,195 +2,534	+19%	+$660K	0.2%	68
2024 Q2	$3.32M	Hold	13,661	–	–	0.15%	93
2024 Q1	$2.04M	Hold	13,661	–	–	0.1%	120
2023 Q4	$2.61M	Hold	13,661	–	–	0.14%	96
2023 Q3	$2.42M	Hold	13,661	–	–	0.15%	95
2023 Q2	$2.59M	Hold	13,661	–	–	0.15%	97
2023 Q1	$2.74M	Hold	13,661	–	–	0.18%	92
2022 Q4	$3.25M	Buy	13,661 +3,522	+35%	+$751K	0.23%	84
2022 Q3	$2.03M	Buy	+10,139	New	+$1.93M	0.14%	106

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silvant Capital Management's ALNY Position: Q2 2026 in Review

Silvant Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.72% in Q2 2026, selling an estimated $39.8K and leaving 18,126 shares worth $5.46M. The position accounts for 0.16% of the portfolio, ranked #82.

Silvant Capital Management first reported a position in ALNY in Q3 2022 and has held it in 16 quarters since. The position peaked at $8.06M in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Silvant Capital Management held 18,126 shares of Alnylam Pharmaceuticals worth $5.46M as of Q2 2026.
Silvant Capital Management sold 132 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $39.8K.
Alnylam Pharmaceuticals made up 0.16% of Silvant Capital Management's portfolio in Q2 2026, its #82 holding.
Silvant Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Silvant Capital Management's Alnylam Pharmaceuticals position peaked at $8.06M in Q3 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.